Vervainioti A.
Energy for Health [12]. 2014
It is well established that low back pain is a common musculoskeletal disorder in adult population and has high social-economic impact. Among therapeutic methods we chose to test those suggested by international literature as effective, such as high intensity laser therapy, versus standard physiotherapy protocol (ultrasound, T.E.N.S., massage, mobilization and exercises). We designed a trial with three therapy groups. The main objective was to compare the efficacy of a specific Nd:YAG laser (HILT) with a standard physiotherapy protocol on low back pain and a combination of the two methods. It was within the scope of this paper to address in detail the variation of pain through pain type and localization for low back pain patients. Analyses showed that a significant number of patients with acute pain gained full recovery (28,8%), while patients affected by chronic pain obtained a significant improvement (31,1%) of pain symptoms, but not healing. Focal pain was healed more effectively than widespread pain. Final assessment showed that standardized physiotherapy (group A) did not manage to bring full recovery to patients, but just improving. Hilterapia® (group C) had better results in comparison with the standardized physioterapeutic approach and showed early analgesic effects. Patients treated with both HILT and standardized physiotherapy showed the higher clinical-functional improvement (group B), when compared with the other groups of patients. The results showed that a therapeutical protocol based on the combination of HILT and standardized physiotherapy may be successfully used to obtain improvement of pain symptoms and early healing in patients with non-specific pain of the lumbar area.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.